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ABSTRACT 
The inflammatory form of epidermolysis bullosa acquisita is caused by autoantibodies 
against type VII collagen (C7), a component of the dermal-epidermal junction. We have 
previously shown that myeloid Src-family kinases mediate skin inflammation triggered 
by anti-C7 antibodies. Here we identify the Syk tyrosine kinase as a critical component 
of autoantibody-induced skin inflammation downstream of Src-family kinases. 
Immobilized C7–anti-C7 immune complexes triggered neutrophil activation and Syk 
phosphorylation in a Src-family kinase-dependent manner. Bone marrow chimeric mice 
lacking Syk in their hematopoietic compartment were completely protected from skin 
inflammation triggered by anti-C7 antibodies despite normal circulating anti-C7 levels. 
Syk deficiency abrogated the accumulation of CXCL2, IL-1β and LTB4 at the site of 
inflammation and resulted in defective in vivo neutrophil recruitment. Syk–/– neutrophils 
had a normal intrinsic migratory capacity but failed to release CXCL2 or LTB4 upon 
activation by immobilized C7–anti-C7 immune complexes, indicating a role for Syk in 
the amplification of the inflammation process. These results identify Syk as a critical 
component of skin inflammation in a mouse model of epidermolysis bullosa acquisita 
and as a potential therapeutic target in epidermolysis bullosa acquisita and other 
mechanistically related inflammatory skin diseases such as bullous pemphigoid. 
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INTRODUCTION 
Typical examples of subepidermal blistering skin diseases are bullous 
pemphigoid and epidermolysis bullosa acquisita, the latter disease having both an 
inflammatory and a non-inflammatory (mechanobullous) form (Ludwig and Zillikens, 
2011; Kim and Kim, 2013). Both bullous pemphigoid and epidermolysis bullosa 
acquisita are caused by autoimmune targeting of components of the dermal-epidermal 
junction and are triggered by autoantibodies against the hemidesmosomal proteins 
BP230/BP180 or the dermal anchoring fibril protein type VII collagen, respectively 
(Schmidt and Zillikens, 2013; Baum et al., 2014; Turcan and Jonkman, 2015). In case 
of bullous pemphigoid and the inflammatory form of epidermolysis bullosa acquisita, 
this leads to local inflammation and disruption of the dermal-epidermal junction, 
mediated by complement activation and leukocyte (mainly eosinophil and neutrophil) 
infiltration (Schmidt and Zillikens, 2013). In contrast, autoantibodies appear to directly 
decrease the adhesive function of the basement membrane without initiating significant 
inflammation in the non-inflammatory form of epidermolysis bullosa acquisita (Kim and 
Kim, 2013). Unfortunately, further details of the pathomechanism of bullous pemphigoid 
and epidermolysis bullosa are poorly understood and, therefore, the therapeutic 
options are rather limited (Kasperkiewicz and Schmidt, 2009).  
A number of in vivo models mimic bullous pemphigoid or the inflammatory form 
of epidermolysis bullosa acquisita by utilizing active or passive immunization against 
components of the dermal-epidermal junction in experimental animals (Iwata et al., 
2015). The most widely used model relies on the passive immunization of mice with 
IgG antibodies against the immunodominant NC1 domain of type VII collagen (Sitaru et 
al., 2005; Sitaru, 2007; Ludwig, 2012). Since this intervention triggers substantial 
inflammation and inflammatory pathway components are critical to disease 
pathogenesis (see below), this model is believed to mimic the inflammatory but not the 
non-inflammatory form of epidermolysis bullosa acquisita. 
Animal models of bullous pemphigoid and epidermolysis bullosa acquisita have 
revealed striking similarities between the pathomechanism of the two disease models. 
Critical components include activating Fc-receptors (Sitaru et al., 2005; Zhao et al., 
2006; Kasperkiewicz et al., 2012; Schulze et al., 2014), the alternative pathway of 
complement activation (Liu et al., 1995; Sitaru et al., 2005; Mihai et al., 2007) as well 
as myeloid cells such as neutrophils (Liu et al., 1997; Chiriac et al., 2007). Our recent 
signaling studies revealed complete protection of mice lacking three Src-family kinases 
expressed in myeloid cells (Hck, Fgr and Lyn) from skin inflammation triggered by 
antibodies against type VII collagen (Kovács et al., 2014), while mice lacking PI3Kβ 
(Kulkarni et al., 2011) or the CARD9 adapter protein (Németh et al., 2016) were 
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partially protected. Additional experiments pointed to a critical role for those molecules 
within the neutrophil compartment in all three cases. 
Syk is a nonreceptor tyrosine kinase primarily expressed in cells of 
hematopoietic origin (Mócsai et al., 2010). Syk is involved in signal transduction of a 
number of tyrosine kinase-coupled receptors including β2-integrins and various Fc-
receptors (Mócsai et al., 2002; Mócsai et al., 2003; Mócsai et al., 2010; Németh et al., 
2016). Src-family kinases are involved in Syk activation in most of those cases (Mócsai 
et al., 2002; Mócsai et al., 2006; Mócsai et al., 2010; Kovács et al., 2014). 
Hematopoietic or neutrophil-specific deletion of Syk protects mice from arthritis 
development in the K/B×N serum-transfer model (Jakus et al., 2010; Elliott et al., 2011) 
and Syk has been proposed to be a potential target in rheumatoid arthritis and other 
autoimmune inflammatory diseases (Mócsai et al., 2010; Weinblatt et al., 2010; 
Geahlen, 2014). However, the role of Syk in autoimmune inflammatory skin diseases is 
still entirely unclear. 
The above findings and the lack of information on the role of Syk in autoimmune 
dermatitis prompted us to test the role of Syk in an in vivo model of the inflammatory 
form of epidermolysis bullosa acquisita in experimental mice. Our results indicate that 
Syk is critically involved in skin inflammation triggered by autoantibodies against type 
VII collagen, identifying Syk as a potential therapeutic target in epidermolysis bullosa 
acquisita and, possibly, other inflammatory skin diseases of similar pathomechanism. 
 
RESULTS 
Neutrophil activation by type VII collagen-containing immune complexes 
We have previously shown that immobilized human serum albumin (HSA)–anti-
HSA immune complexes trigger robust activation of neutrophils (Jakus et al., 2008). To 
determine whether immune complexes containing dermo-epidermal junctional proteins 
can also activate neutrophils, we generated immobilized immune complexes using a 
His-tagged fragment of the immunodominant NC1 domain of murine type VII collagen 
(His-C7) and rabbit polyclonal IgG (anti-C7) against the GST-fusion protein of the same 
fragment (Sitaru et al., 2002; Csorba et al., 2010). Plating wild-type mouse neutrophils 
on such immobilized immune complexes triggered robust activation of the cells as 
measured by the release of superoxide anions (Fig 1a; p = 4 × 10-6). Neutrophil 
activation required both the antigen and the antibody components (Fig 1a). His-C7–
anti-C7 immune complexes also triggered spreading of the cells over the immune 
complex-coated surface (Fig 1b). 
To test the antigen specificity of neutrophil activation, ELISA plates were coated 
with His-C7 or HSA, blocked and then incubated with anti-C7 or anti-HSA antibodies. 
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As shown in Fig 1c, neutrophils mounted a robust respiratory burst in the presence of 
matching antigen-antibody pairs (His-C7 with anti-C7 or HSA with anti-HSA; p = 8 × 10-
6 and p = 1.9 × 10-3, respectively) but not when non-matching antigen-antibody pairs 
were used. 
Taken together, type VII collagen-containing immune complexes are able to 
specifically activate neutrophil functions. 
 
Src-family kinases mediate neutrophil respiratory burst and Syk activation by 
type VII collagen-containing immune complexes 
We have recently shown that the Src-family kinases Hck, Fgr and Lyn are 
critically involved in neutrophil activation triggered by HSA–anti-HSA immune 
complexes (Kovács et al., 2014). To test whether this also applies to type VII collagen-
containing immune complexes, we tested the responses of Hck–/–Fgr–/–Lyn–/– (3× SFK 
KO) neutrophils. As shown in Fig 1d, 3× SFK KO neutrophils failed to release 
superoxide under such conditions. 
Syk is a non-receptor tyrosine kinase activated downstream of Src-family 
kinases in several immunoreceptor-induced signaling pathways (Mócsai et al., 2010; 
Futosi et al., 2013). We next tested whether this is also true for neutrophil activation by 
type VII collagen-containing immune complexes. Wild-type neutrophils plated on 
immobilized His-C7–anti-C7 immune complexes showed Syk phosphorylation (a 
measure of Syk activation) whereas no such response could be observed in 3× SFK 
KO neutrophils (Fig 1e; see also the entire blots in Fig S1). 
Taken together, neutrophil activation by type VII collagen-containing immune 
complexes triggers Syk activation downstream of the Src-family kinases Hck, Fgr and 
Lyn. 
 
Generation and characterization of Syk–/– bone marrow chimeras 
The above findings raised the possibility that Syk may also be involved in anti-
C7 antibody-induced skin inflammation. Unfortunately, the perinatal lethality of 
genetically Syk-deficient (Syk–/–) animals (Turner et al., 1995; Abtahian et al., 2003; 
Mócsai et al., 2010) did not allow us to test this in intact animals. To overcome that 
problem, we generated bone marrow chimeras lacking Syk only in their hematopoietic 
compartment (termed Syk–/– bone marrow chimeras) by transplanting fetal liver cells of 
Syk–/– fetuses into lethally irradiated wild-type recipients (Mócsai et al., 2002). Control 
chimeras (termed wild-type bone marrow chimeras) were generated by parallel 
transplantation of Syk+/+ or Syk+/– fetal liver cells. Differential expression of CD45 alleles 
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in the donor (CD45.2) and the recipient (CD45.1) cells allowed identification of donor- 
and recipient-derived cells. As shown in Fig 2a, practically all peripheral blood 
neutrophils of wild-type or Syk–/– bone marrow chimeras expressed the donor-derived 
CD45.2 allele, indicating complete repopulation of the hematopoietic compartment by 
donor-derived cells. In addition, Syk was present in lysates of freshly isolated 
neutrophils and platelets, as well as of bone marrow-derived macrophages and mast 
cells, from wild-type but not Syk–/– bone marrow chimeras (Fig 2b). Therefore, we were 
able to replace the wild-type hematopoietic compartment of the recipient mice with 
donor-derived (e. g. Syk–/–) cells. 
We did not observe any difference in circulating neutrophils numbers between 
wild-type and Syk–/– bone marrow chimeras (Fig 2c; p = 0.69), and similar numbers of 
bone marrow neutrophils could be isolated from chimeras of the two genotypes (Fig 2d; 
p = 0.37). In addition, Syk–/– neutrophils expressed normal levels of the neutrophil 
maturation marker Ly6G, the β2 integrin component CD18, the major neutrophil 
chemokine receptor CXCR2, as well as the Fc-receptors FcγRII/III and FcγRIV (Fig 
2e). Therefore, the Syk–/– mutation did not interfere with the generation or maturation of 
neutrophils, or the expression of critical cell surface receptors. 
 
Syk–/– bone marrow chimeras are completely protected from skin inflammation 
triggered by anti-C7 antibodies 
We next subjected wild-type and Syk–/– bone marrow chimeras to repeated 
subcutaneous injection of anti-C7 or normal rabbit IgG/PBS, as a model of 
inflammatory autoimmune blistering skin diseases (Sitaru et al., 2005). Our previous 
studies have indicated a critical role for the Fc portion of the pathogenic antibodies in 
this model (Sitaru et al., 2005). As shown in Fig 3a, wild-type chimeras treated with 
anti-C7 antibodies developed significant signs of skin inflammation at several body 
areas, ranging from loss of the superficial layer of the skin (most prominent in the 
buccal/periorbital area) to severe inflammation and scarring at the most severely 
affected places (most prominent on the ears). Importantly, Syk–/– bone marrow 
chimeras were completely protected from development of all those skin inflammatory 
changes (Fig 3a). 
Quantification of the overall skin changes revealed that the percentage of the 
affected body surface area gradually increased over the assay period in wild-type 
chimeras, whereas no signs of the disease could be observed in Syk–/– chimeras (Fig 
3b; p = 0.022). Similarly, the overall clinical score also gradually increased during the 
assay period in wild-type chimeras without any signs of the disease in Syk–/– chimeras 
(Fig 3c; p = 6.0 × 10-3). 
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A possible explanation for the above findings could be that the Syk–/– mutation 
affects the metabolism of the injected pathogenic antibodies. However, no differences 
in circulating anti-C7 antibody titers could be observed between the wild-type and Syk–
/– genotypes (Fig 3d; p = 0.69). 
We next tested skin inflammation by histological analysis of the ear tissue. As 
shown in Fig 3e, anti-C7 antibody treatment triggered substantial thickening of the ear 
of wild-type chimeras with prominent leukocyte infiltration. However, no such 
inflammatory changes could be observed in Syk–/– bone marrow chimeras. 
Taken together the Syk–/– mutation blocks the capability of anti-C7 antibodies to 
trigger skin inflammation both at the macroscopic and microscopic levels, without 
affecting their removal from the circulation. 
 
The Syk–/– mutation blocks neutrophil recruitment without affecting the intrinsic 
migratory capacity of neutrophils 
The inflammatory form of epidermolysis bullosa acquisita is characterized by a 
significant influx of granulocytes (eosinophils and neutrophils) which are likely involved 
in the inflammation process (Schmidt and Zillikens, 2013). As shown in Fig 4a, anti-C7 
antibodies triggered dramatic influx of neutrophils to the ear of wild-type bone marrow 
chimeras, which appears to be a peculiarity of this mouse model (as compared to the 
dominant infiltration by eosinophils in the inflammatory form of human epidermolysis 
bullosa acquisita). Importantly, and in agreement with the histological pictures (Fig 3e), 
no such accumulation of neutrophils could be observed in Syk–/– chimeras (Fig 4a; p = 
7.7 × 10-3). 
The simplest explanation for the above findings would be an intrinsic migration 
defect of Syk–/– neutrophils. However, we previously reported normal migration of Syk–/– 
neutrophils towards various proinflammatory agonists both under in vitro and in vivo 
conditions (Mócsai et al., 2002; Mócsai et al., 2003). To test this question in anti-C7-
induced skin inflammation, we generated mixed bone marrow chimeras carrying 
leukocytes (including neutrophils) from both CD45.1-expressing wild type and CD45.2-
expressing wild type or Syk–/– bone marrow cells. Such chimeras developed signs of 
inflammation due to the presence of wild type cells. Comparative flow cytometric 
analysis of CD45.1/2 expression in the inflammatory infiltrate and the peripheral blood 
then allowed us to compare the migration of wild type and Syk–/– neutrophils within the 
same animal. The percentage values for the peripheral blood and ear samples are 
presented in Fig 4b, whereas the relative migratory capacity of the CD45.2 (wild type or 
Syk–/–) cells relative to the CD45.1 (wild type) reference cells (calculated based on the 
data in Fig 4b) is shown in Fig 4c. As expected, the percentage of wild type CD45.2 
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cells was comparable in the peripheral blood and the inflamed ear in the chimeras 
transplanted with cells from two wild type donors (WT:WT chimeras; Figs 4b-c). 
Importantly, the percentage of Syk–/– CD45.2 cells in the inflamed ear tissue was also 
similar to that in the peripheral blood in WT:Syk–/– chimeras (Fig 4b), and the calculated 
relative migration of Syk–/– cells was similar to, or even higher than that of wild type 
cells (Fig 4c; p = 4.4 × 10-6). Those results indicate that Syk–/– neutrophils are 
intrinsically capable of migrating to the site of inflammation, arguing against an intrinsic 
migration defect in Syk–/– neutrophils. 
Taken together, although neutrophils failed to accumulate in the ear of anti-C7 
antibody-treated Syk–/– bone marrow chimeras, this was not due to an intrinsic 
migration defect of Syk–/– neutrophils since those cells were able to accumulate at the 
site of inflammation when wild type cells were also present in mixed bone marrow 
chimeras. 
 
The Syk–/– mutation blocks the accumulation of proinflammatory mediators in 
vivo 
An alternative explanation for the abrogation of neutrophil accumulation in Syk–
/– chimeras (Fig 4a) is that Syk deficiency may interfere with the development of a 
proper inflammatory (chemoattractant) microenvironment. As shown in Fig 4d, 
systemic administration of anti-C7 antibodies dramatically increased tissue levels of 
CXCL2 (MIP-2) in the ear of wild-type but not Syk–/– bone marrow chimeras (p < 10-17). 
Similarly, hematopoietic deficiency of Syk abrogated the accumulation of the 
proinflammatory cytokine IL-1β (Fig 4e; p = 1.6 × 10-7). Moreover, anti-C7 antibodies 
also moderately increased the level of the lipid mediator LTB4 (a major neutrophil 
chemoattractant in various inflammatory conditions), in wild-type but not Syk–/– bone 
marrow chimeras (Fig 4f; p = 0.038). 
 Taken together, hematopoietic deficiency of Syk somehow prevented the 
accumulation of various proinflammatory agonists at the site of inflammation, likely 
leading to the defective accumulation of Syk–/– neutrophils and subsequent protection 
from clinical disease. 
 
Syk–/– neutrophils fail to respond to type VII collagen-containing immune 
complexes in vitro 
Since neutrophils are capable of releasing various chemokines, cytokines and 
lipid mediators (Kovács et al., 2014; Tecchio et al., 2014; Németh et al., 2016), we 
hypothesized that the above in vivo findings may be due to defective responses of Syk–
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/– neutrophils to type VII collagen-containing immune complexes. Indeed, Syk–/– 
neutrophils failed to release superoxide (Fig 5a; p = 8.6 × 10-4) or spread over the 
adhesive surface (Fig 5b) when plated on immobilized His-C7–anti-C7 immune 
complexes. In addition, wild-type neutrophils released large amounts of both CXCL2 
and LTB4, whereas no such responses could be observed in Syk–/– samples (Figs 5c-d; 
p = 3.8 × 10-10 and 1.1 × 10-16, respectively). Those results suggest that Syk is 
indispensable for neutrophil activation by type VII collagen-containing immune 
complexes, explaining the defective development of an in vivo inflammatory 
environment in Syk–/– bone marrow chimeras. 
 
DISCUSSION 
Together with an accompanying paper (Samavedam et al., submitted), here we 
report for the first time that the Syk tyrosine kinase is indispensable for an in vivo model 
of the inflammatory form of epidermolysis bullosa acquisita in experimental mice. 
These studies raise the possibility that Syk may be a suitable therapeutic target in that 
disease and, possibly, in other diseases with a similar pathogenesis. 
Syk has diverse biological functions (Mócsai et al., 2010), primarily by 
mediating signaling from immunoreceptors such as Fc-receptors. Fc-receptors play a 
critical role in mouse models of bullous pemphigoid and the inflammatory form of 
epidermolysis bullosa acquisita (Sitaru et al., 2005; Zhao et al., 2006; Kasperkiewicz et 
al., 2012; Schulze et al., 2014). Together with our studies on the role of Src-family 
kinases (Kovács et al., 2014) and CARD9 (Németh et al., 2016), our experiments 
suggest that anti-C7-induced skin inflammation is mediated by Syk linking Fc receptor-
mediated activation of Src-family kinases to downstream signaling through the CARD9 
adapter protein. This is reminiscent of signal transduction in K/B×N serum-transfer 
arthritis and recognition of fungal pathogens (Gross et al., 2009). 
In agreement with other studies on neutrophil function (Németh and Mócsai, 
2012; Mócsai, 2013), our results suggest an important role for neutrophils in certain 
inflammatory autoimmune subepidermal blistering skin disease models. Our results of 
defective in vivo recruitment of Syk–/– neutrophils despite apparently normal intrinsic 
migratory capacity (Figs 4a-c) and the defective accumulation of neutrophil-attracting 
proinflammatory mediators (CXCL2 and LTB4) in vivo (Figs 4d,f) and in in vitro 
neutrophil assays (Figs 5c-d) suggest that the principal role of Syk is to promote 
feedback amplification loops through proinflammatory mediator release by neutrophils 
(Németh and Mócsai, 2016). Though we cannot exclude the role of Syk expression in 
another cell type, neutrophil-specific deletion of Syk completely protected mice from 
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anti-C7-induced skin pathology (T. N. and A. M., unpublished observation), indicating 
the central role for neutrophil-derived Syk in the disease process. 
Besides identifying Syk as a critical player in autoantibody-induced skin 
inflammation, our results also raise a number of novel questions. What is the role of 
Syk in the initial, immunization phase of autoimmune bullous skin diseases, or the very 
first steps of anti-C7-induced skin inflammation before the initiation of the neutrophil-
mediated feedback amplification process? Would it be possible to document differential 
chemokine gene expression of wild type and Syk–/– neutrophils in mixed bone marrow 
chimeras? Do our conclusions also apply to other autoimmune subepidermal blistering 
skin diseases where the autoantigen is other than type VII collagen or where the 
inflammatory component is less pronounced? How much can we extrapolate our 
findings on mouse models to human autoimmune and other inflammatory skin 
diseases? Those and other questions need to be addressed by future follow-up 
studies. 
Parallel to our own study initiated by the relationship between Src-family 
kinases and Syk (Berton et al., 2005; Kovács et al., 2014; Futosi and Mócsai, 2016), 
another study described in an accompanying paper (Samavedam et al., submitted) 
also identified Syk as a core signaling hub in the inflammatory form of epidermolysis 
bullosa acquisita. While both papers conclude that Syk is critical for disease 
development, they also complement each other by addressing different additional 
aspects, such as additional signaling and mechanistic experiments in our study and 
bioinformatics and pharmacological aspects in the accompanying paper. 
The pharmacological therapy of bullous pemphigoid and epidermolysis bullosa 
acquisita still relies on rather nonspecific immunosuppressive and anti-inflammatory 
agents. We have identified Syk as a critical component of autoantibody-induced skin 
inflammation in experimental mice. Though there are clear differences between our 
mouse model and the corresponding human disease(s) (passive vs. active 
immunization; neutrophils vs. eosinophils dominating the inflammatory infiltrate; 
respectively), we believe that our mouse studies relatively closely mimic important 
aspects of human pathology. Syk has emerged as a potential therapeutic target in 
other autoimmune inflammatory diseases such as rheumatoid arthritis, as well as in 
Syk-dependent hematologic malignancies (Geahlen, 2014). Though fostamatinib, the 
first Syk inhibitor reaching clinical development raised safety concerns likely related to 
its poor specificity (Anastassiadis et al., 2011; Genovese et al., 2014; Weinblatt et al., 
2014; Rolf et al., 2015), there is a large effort from the pharmaceutical industry to 
develop novel and much more specific Syk inhibitors (Norman, 2014; Walker and 
Croasdell, 2016). Our results, together with those described in the accompanying 
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paper (Samavedam et al., submitted) suggest that such Syk-specific inhibitors may be 
suitable for the pharmacological control of certain inflammatory autoimmune 
subepidermal blistering skin diseases such as the inflammatory form of epidermolysis 
bullosa acquisita or, possibly, the mechanistically related bullous pemphigoid. 
 
MATERIALS AND METHODS 
Animals 
Mice carrying a deleted Syk allele (Syktm1Tyb, referred to as Syk–) were from 
Victor Tybulewicz (Turner et al., 1995) and kept in heterozygous form. Recipients 
carrying the CD45.1 allele on the C57BL/6 genetic background (B6.SJL-Ptprca mice 
from the Jackson Laboratory) were lethally irradiated by 11 Gy from a 137Cs source 
using a Gamma-Service Medical D1 irradiator and then injected intravenously with fetal 
liver cells from Syk–/– and control fetuses obtained from timed mating of Syk+/– carriers 
(Mócsai et al., 2002; Jakus et al., 2010). Hcktm1Hev/tm1HevFgrtm1Hev/tm1HevLyntm1Sor/tm1Sor 
triple knockout mice (referred to as Hck–/–Fgr–/–Lyn–/– or 3× SFK KO mice) were 
described previously (Meng and Lowell, 1998; Kovács et al., 2014). Mice were kept in 
individually sterile ventilated cages (Tecniplast) in a conventional facility. All animal 
experiments were approved by the Animal Experimentation Review Board of the 
Semmelweis University. 
 
Autoantibody-induced skin blistering model 
The murine model of the inflammatory form of human epidermolysis bullosa 
acquisita was triggered by systemic administration of antibodies against collagen type 
VII which triggers skin inflammation through the antibody Fc portions (Sitaru et al., 
2005). Rabbits were immunized with a GST-fusion protein containing a fragment of the 
immunodominant NC1 domain of murine type VII collagen (GST-C7), followed by total 
IgG preparation (anti-C7) (Sitaru et al., 2005; Csorba et al., 2010). The reactivity of the 
antibody preparation was tested with a His-tagged murine type VII collagen fragment 
(His-C7) (Csorba et al., 2010). Normal rabbit IgG (Sigma) or PBS (Thermo Fisher) was 
used as control. 
Twelve mg pathogenic or control IgG was injected subcutaneously under 
isoflurane anaesthesia on Days 0, 2, 4, 6 and 8 (60 mg total IgG/mouse). Disease 
onset and progression was followed by clinical assessment, while quantitative scoring 
was based on the specific dermatological abnormalities and the size of the affected 
skin area (Sitaru et al., 2005; Kovács et al., 2014; Németh et al., 2016). Serum anti-C7 
levels were determined by ELISA using His-C7. For histological analysis, mice were 
sacrificed on Day 8 (when no open wounding had occurred), their ears were fixed in 
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paraformaldehyde, dehydrated, embedded in paraffin, sectioned at 9 μm thickness and 
stained with hematoxylin and eosin.  
 
In vivo analysis of neutrophil accumulation 
Wild type and Syk-deficient bone marrow chimeras were injected with control or 
pathogenic IgG. On Day 8-10, mice were sacrificed and their ears were removed. The 
samples were digested with Liberase II (Roche) (Weber et al., 2015). Single cell 
suspensions were obtained and neutrophil numbers were determined by flow cytometry 
on the basis of their forward and side scatter characteristics and Ly6G-positivity (Clone 
1A8, BD Biosciences). 
 
In vivo neutrophil migration 
A competitive migration assay in mixed bone marrow chimeras was used to 
assess in vivo migration of neutrophils (Mócsai et al., 2002; Jakus et al., 2009; Kovács 
et al., 2014). Wild type (C57BL/6) or Syk–/– bone marrow cells (carrying the CD45.2 
allele) were mixed at varying ratios with bone marrow cells from congenic mice 
expressing CD45.1 on the C57BL/6 genetic background. The cell suspension was 
injected intravenously into lethally irradiated CD45.1-expressing recipient mice. After 
bone marrow repopulation, the chimeras were subjected to experimental epidermolysis 
bullosa acquisita and their ears were digested (before any open wounds occurred). The 
percentage of CD45.2-expressing neutrophils was analyzed by flow cytometry with 
staining for Ly6G and CD45.2 (Clone 104, BD Biosciences). 
Relative migration of the CD45.2-positive neutrophils (relative to the CD45.1-
expressing wild type cells) was calculated as described (Jakus et al., 2009). 
 
Isolation and activation of neutrophils 
Mouse neutrophils were isolated from the bone marrow by Percoll (GE 
Healthcare) gradient centrifugation (Mócsai et al., 2003). Neutrophil assays were 
performed at 37 °C in HBSS (GE Healthcare) supplemented with 20 mM HEPES, pH 
7.4 or in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma). Cell surface molecule 
expression was detected by anti-Ly6G-PE (Clone 1A8), anti-CD18-Biotin (Clone 
C71/16), anti-CXCR2-PE (Clone #242216, R&D Systems), anti-FcγRII/III (Clone 
2.4G2) and anti-FcγRIV-PE (Clone 9E9) antibodies. Where required, secondary 
staining with Streptavidin-PE or mouse anti-rat-FITC (Clone MRK-1) was performed. If 
not otherwise stated, the antibodies were from BD Biosciences.  
Immobilized immune complex-coated surfaces were obtained by binding His-C7 
at 20 μg/ml to Nunc MaxiSorp F96 plates (Thermo Fisher) or tissue culture dishes, 
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blocked and then treated with anti-C7 at a 1:10 dilution, otherwise as described  (Jakus 
et al., 2008). Human serum albumin (HSA) and anti-HSA immune complexes were 
generated as described (Jakus et al., 2008). 
For the analysis of mediator release, neutrophils were stimulated for 1 (LTB4) or 
6 (cytokines) hours, and supernatants were collected for further analysis (Kovács et al., 
2014; Németh et al., 2016). Superoxide release was followed by a cytochrome c 
reduction test (Németh et al., 2010). 
 
Isolation of other cell types 
Platelets were isolated from peripheral blood by mild centrifugation in the 
presence of heparin. Mast cells were cultured from the bone marrow by murine IL-3 
and stem cell factor (both from Peprotech). Macrophages were obtained by culturing 
bone marrow cells in the presence of recombinant murine M-CSF from a conditioned 
medium (Kertész et al., 2012). 
 
Analysis of inflammatory mediators 
The removed ears were either crushed under liquid nitrogen and lysed by a 
Triton-based buffer or were cut into small pieces and were digested. The release of 
mediators was tested from the ear lysates, the cell-free supernatants of digested 
samples or of in vitro stimulated neutrophils. The levels of CXCL2, IL-1β and LTB4 
were tested by commercial ELISA kits (R&D Systems). 
 
Biochemical studies 
For analysis of Syk phosphorylation, neutrophils were plated on immune 
complex-covered 6-cm tissue culture dishes, incubated for 10 min at 37 °C, and lysed 
on ice (adherent and nonadherent cells combined) (Kovács et al., 2014).  
Immunoprecipitation was performed by an anti-Syk antibody (5F5, BioLegend) followed 
by capturing with Protein G-Agarose (Invitrogen) (Mócsai et al., 2000; Mócsai et al., 
2004; Mócsai et al., 2006; Németh et al., 2016). Whole cell lysates from the same 
experiments were used as controls. 
Samples were run on SDS-PAGE and immunoblotted using antibodies against 
phosphotyrosine (Clone 4G10, Merck Millipore), Syk (N19, Santa Cruz Biotechnology) 
or β-actin (Clone AC-74, Sigma) followed by incubation with peroxidase-labeled 
secondary antibodies (GE Healthcare). The signal was developed using the ECL 
system (GE Healthcare) and exposed to X-ray films. 
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Presentation of the data and statistical analysis 
Experiments were performed the indicated number of times. Quantitative 
graphs and kinetic curves show mean and SEM from all independent in vitro 
experiments or from all individual mice from the indicated number of experiments. 
Statistical analyses were carried out using one- or two-way (factorial) ANOVA (with 
treatment and genotype being the two independent variables). Area under the curve 
(AUC) was used for statistical analysis in kinetic measurements. P values below 0.05 
were considered statistically significant. 
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FIGURE LEGENDS 
Figure 1 
Type VII collagen-containing immune complexes trigger neutrophil activation and Syk 
phosphorylation through Src-family kinases 
(a) Respiratory burst of wild-type (WT) mouse neutrophils plated on surfaces treated with His-
C7 and/or anti-C7. (b) His-C7–anti-C7 immune complexes trigger spreading of wild-type 
neutrophils. (c) Specificity of the His-C7‒anti-C7- and HSA–anti-HSA-induced responses. (d-e) 
Src-family kinases are essential for His-C7‒anti-C7 immune complex-triggered superoxide 
release and Syk-phosphorylation. Kinetic curves and graphs in a, c and d show mean and SEM 
of 2-3 independent experiments. In Panels a and d, control data points were subtracted. Panels 
b and e are representative of 2-3 independent experiments. See the text for actual p values. C7, 
type VII collagen fragment; HSA, human serum albumin; 3× SFK KO, Hck–/–Fgr–/–Lyn–/–. 
 
Figure 2 
Characterization of wild-type and Syk–/– bone marrow chimeras and their neutrophils 
(a) Flow cytometric analysis of the donor-specific CD45.2 epitope in peripheral blood neutrophils 
tested 4 weeks after bone marrow (BM) transplantation. (b) Immunoblot analysis of Syk 
expression in various cell types from wild-type (WT) and Syk‒/‒ bone marrow chimeras. (c) 
Circulating neutrophil (PMN) counts in wild-type and Syk‒/‒ chimeras. (d) Average neutrophil 
number isolated from the bone marrow of the different chimeras. (e) Cell surface molecule 
expression of wild-type and Syk‒/‒ bone marrow-isolated neutrophils. Panels a, b and e are 
representative of 3-10 independent experiments. Graphs in Panel c and d show mean and SEM 
from 9-11 mice. See the text for actual p values. 
 
Figure 3 
Syk is required for experimental epidermolysis bullosa acquisita 
Skin disease was triggered in wild-type (WT) or Syk–/– bone marrow chimeras by anti-C7 
antibodies and was followed by photographing the heads, the trunks and the ears (a), clinical 
assessment of the body surface affected (b) and the overall disease severity (c). (d) Serum anti-
C7 levels were tested by ELISA. (e) Hematoxylin and eosin stained ear histological sections are 
presented from WT and Syk–/– chimeras. The right images were magnified from the pictures 
seen on the left (10x original magnification). Representative images (a, e) or mean and SEM (b-
c) from 3 control and 12-13 anti-C7-treated mice per genotype from 3 independent experiments 
are shown. Panel d shows mean and SEM from 2-3 control and 9-11 anti-C7-treated mice from 
2 independent experiments. See the text for actual p values. 
 
Figure 4 
Syk is essential for forming the inflammatory environment  
(a) The accumulation of neutrophils in the ear upon anti-C7 injection was determined by flow 
cytometry. (b-c) Mixed bone marrow chimeras with CD45.1-expressing wild type (WT) and 
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CD45.2-expressing WT or Syk–/– hematopoietic cells were injected with anti-C7 antibodies and 
neutrophil accumulation was determined by flow cytometric analysis. In Panel b, each dot 
represents an individual ear, while Panel c shows the relative migration of WT and Syk–/– 
neutrophils. (d-f)  Decreased in vivo CXCL2, IL-1β and LTB4 levels in the ears of Syk-deficient 
chimeras. Graphs represent mean and SEM from 3-5 (a) or 2-6 mice (c), 3-4 control or 5-7 anti-
C7-treated mice (d-f) per group from 2-3 independent experiments. See the text for actual p 
values. 
 
Figure 5 
Syk is required for neutrophil responses on immobilized His-C7‒anti-C7 immune complexes 
Respiratory burst (a), cell spreading (b), CXCL2 (c) and LTB4 release (d) of wild-type (WT) and 
Syk‒/‒neutrophils. Curves in Panel a show mean and SEM of 3 independent experiments; 
control data points were subtracted. Panel b is representative of 3 independent experiments. 
Graphs in (c-d) show mean and SEM from 3 independent experiments. See the text for actual p 
values. 
 
Supplementary Figure 1 
Western blot images with more details 
Western blot images showing Syk phosphorylation and Syk expression in Syk-
immunoprecipitated samples and whole cell lysates of neutrophils from Fig 1e. IP, 
immunoprecipitation; 3× SFK KO, Hck–/–Fgr–/–Lyn–/–; WB, Western blot; WCL, whole cell lysate; 
WT, wild-type 






